Tyra reports first Phase 2 SURF302 data for dabogratinib in bladder cancerNov 10Quarterly updatedabogratinibTyra Biosciences, Inc
Tyra reports initial Phase 2 data for oral dabogratinib in bladder cancerSep 9Clinical readoutdabogratinibTyra Biosciences, Inc
Tyra reports Q2 2026 results, sets September readout for dabogratinib bladder cancer trialAug 4Quarterly updatedabogratinibTyra Biosciences, Inc